{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:46:00Z","timestamp":1773362760475,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.ophtha.2011.04.028","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T19:22:46Z","timestamp":1547580166000},"page":"1227-1228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Retinopathy of Prematurity in the Time of Bevacizumab: Incorporating the BEAT-ROP Results into Clinical Practice"],"prefix":"10.1016","volume":"118","author":[{"given":"Darius M.","family":"Moshfeghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audina M.","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2011.04.028_bib1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2011.04.028_bib2","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2011.04.028_bib3","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nm721","article-title":"Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice","volume":"8","author":"Compernolle","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.ophtha.2011.04.028_bib4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","article-title":"Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin)","volume":"26","author":"Shahar","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2011.04.028_bib5","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.ophtha.2009.05.020","article-title":"Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor","volume":"116","author":"Miki","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2011.04.028_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2011.04.028_bib7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaapos.2009.03.006","article-title":"Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema","volume":"13","author":"Al-Dhibi","year":"2009","journal-title":"J AAPOS"},{"key":"10.1016\/j.ophtha.2011.04.028_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jaapos.2009.06.003","article-title":"Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern","volume":"13","author":"Avery","year":"2009","journal-title":"J AAPOS"},{"key":"10.1016\/j.ophtha.2011.04.028_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00006982-199703000-00009","article-title":"Morphometric analysis of pars plana development in humans","volume":"17","author":"Hairston","year":"1997","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2011.04.028_bib10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ajo.2007.10.027","article-title":"Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach","volume":"145","author":"Vinekar","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.04.028_bib11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1542\/peds.2005-2749","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"117","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.ophtha.2011.04.028_bib12","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.ophtha.2004.02.005","article-title":"Involution of threshold retinopathy of prematurity after diode laser photocoagulation","volume":"111","author":"Coats","year":"2004","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642011004155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642011004155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:00:29Z","timestamp":1758981629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642011004155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0161642011004155"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2011.04.028","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717297974.792752830","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retinopathy of Prematurity in the Time of Bevacizumab: Incorporating the BEAT-ROP Results into Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2011.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}